As evidenced by recent studies, the anti-AnxA2 antibodies detected in severely infected COVID-19 patients suggest that AnxA2 expression is increased following SARS-CoV-2 infection, which could disrupt insulin signaling via the galectin-3 or NF-κB pathways, resulting in insulin resistance and hyperglycemia [42,135,136]. The gene discussed is INS; the disease is Hyperglycemia.